NCT05166694 is a NA clinical trial of Drug-Drug Interaction Profile in Cancer, sponsored by University of Chicago.

Who is sponsoring NCT05166694?

NCT05166694 is sponsored by University of Chicago.

What drugs are being tested in NCT05166694?

Interventions in NCT05166694: Drug-Drug Interaction Profile, Drug-Gene Interaction Profile, Standard of Care.

What condition does NCT05166694 study?

NCT05166694 studies Cancer, Advanced Cancer, Advanced Solid Tumor, Mental Health Issue, Behavior Disorders.

Is NCT05166694 still recruiting?

NCT05166694 is currently recruiting now. Last updated 4 March 2026.

Last reviewed 2026-03-04 · How we verify

NCT05166694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions

Recruiting now NA Last updated 4 March 2026

What this trial tests

NA trial testing Drug-Drug Interaction Profile in Cancer in 1,300 participants. Currently enrolling.

Timeline

30 November 2022

Primary endpoint
1 November 2027

1 November 2027

Quick facts

Lead sponsor	University of Chicago
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,300
Start date	30 November 2022
Primary completion	1 November 2027
Estimated completion	1 November 2027
Sites	1 location across United States

Drugs / interventions tested

Drug-Drug Interaction Profile
Drug-Gene Interaction Profile
Standard of Care

Conditions studied

Cancer — all drugs for Cancer →
Advanced Cancer — all drugs for Advanced Cancer →
Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Mental Health Issue — all drugs for Mental Health Issue →

Sponsor

University of Chicago

Who can join

18 and older, any sex, with Cancer or Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether a consultation with a Personalized Therapeutics Clinic, or PTC, will help participants lower the risk for side effects (drug-drug interactions and drug-gene interactions) when taking many medications and help providers improve prescribing decisions for participants. A PTC is a clinical that will test your genes to gather information about your health that may help guide prescribing advice and offer you new information about your prescriptions. Doctors leading this study will look for variations (differences) in your genes that may suggest that you are at greater risk of having side effects or a greater chance of benefiting from certain medications. Individuals in this study will participate for roughly 9 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluating Perceived Value of Pharmacogenomic Testing After a Personalized Therapeutics Clinic Consultation.
Chen T, Andriessen AS, Jack M, George D, et al · · 2026 · PMID 41949895 · DOI 10.1111/cts.70537

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other University of Chicago trials

Trials by the same sponsor.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05166694 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chicago
Last refreshed: 4 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05166694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing